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SUMMARY – Th e aim of this prospective, non-randomized interventional study was to assess 
electrophysiological eﬀ ects, eﬃ  cacy and safety of intravenous propafenone in termination of atrio-
ventricular nodal reentrant tachycardia (AVNRT) and orthodromic atrioventricular reentrant ta-
chycardia (AVRT). Th is single-center study was carried out at Department of Cardiology, Sestre 
milosrdnice University Hospital in Zagreb, Croatia, between January 1, 2005 and December 31, 
2006. Eligibility requirements were fulﬁ lled by a total of 70 patients with AVNRT (n=37) and 
AVRT (n=33). Th e intervention consisted of the electrophysiological study aimed at inducing ta-
chycardia, followed by intravenous administration of 2 mg/kg propafenone in both groups. Th e 
main outcome measures were safety and eﬃ  cacy of 2 mg/kg intravenous propafenone in tachycardia 
termination and re-induction. Out of 37 patients with AVNRT, propafenone managed to terminate 
it in 28 (75.7%) patients, while tachycardia was not inducible in 25 (67.56%) patients. Out of 33 
patients with AVRT, propafenone managed to terminate AVRT in 29 (87.9%) patients, while ta-
chycardia was not inducible in 22 (66.66%) patients. Th e overall propafenone eﬃ  cacy in tachycardia 
termination was 81.42%. No propafenone-related adverse eﬀ ects were recorded during the study 
period. Propafenone was found to be a safe and eﬀ ective anti-arrhythmic drug and can be justiﬁ ably 
administered for AVNRT and AVRT termination. It could be considered as an alternative to adeno-
sine and verapamil. 
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Introduction
Atrioventricular reentrant tachycardia (AVRT) 
and atrioventricular nodal reentrant tachycardia 
(AVNRT) account for 90% of all supraventricular 
narrow QRS tachycardia cases1. In AVNRT, reen-
try occurs through two anatomical pathways situated 
within, or just next to the atrioventricular (AV) node 
(‘the slow and the fast pathway’), whereas in AVRT 
reentry occurs through the AV node and the accessory 
pathway2,3. Th ere are four supraventricular tachycardia 
(SVT) treatment modalities: drugs (which include 
those aimed at tachycardia termination and preven-
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tion), percutaneous radiofrequency ablation, cardiac 
pacing (transesophageal pacing), and surgery. 
Th e mechanism of AVNRT and AVRT termina-
tion by virtue of pharmacotherapy (i.e. antiarrhyth-
mics) may also be described as the eﬀ orts aiming at 
slowdown of the conductive pace of the AV node or 
the accessory pathway. Propafenone impacts sodium-
dependent conductivity through the fast AV nodal 
and accessory pathway4. Propafenone administration 
is indicated for conversion of recent onset atrial ﬁ bril-
lation, but is much less used for AVNRT and AVRT 
termination5,6. 
According to the joint 2003 guidelines issued by 
the American College of Cardiology, American Heart 
Association and European Society of Cardiology 
(ACC/AHA/ESC), drugs of choice for AVNRT and 
AVRT termination in cases of vagal maneuver failure 
are adenosine and verapamil. Propafenone and ﬂ ecain-
ide are IC antiarrhythmics used as long- term therapy 
aimed at prevention of tachycardia recurrence, but not 
at tachycardia termination5.
Th e aim of this study was to evaluate the safety and 
eﬃ  cacy of intravenous propafenone in termination of 
both AVNRT and AVRT, as well as to evaluate the 
electrophysiological eﬀ ects of propafenone on cardiac 
conductivity. Primary endpoint of this study was the suc-




Th is prospective non-randomized interventional 
study was performed at Department of Cardiol-
ogy, Sestre milosrdnice University Hospital, Zagreb, 
Croatia, between January 1, 2005 and December 31, 
2006. Th e study was approved by the Hospital Board 
of Ethics. Prior to inclusion, an informed consent was 
obtained from all patients enrolled in the study. 
Patients
Th e study included 70 patients, of them 37 with 
AVNRT (group 1) and 33 with AVRT (group 2), treated 
at Department of Cardiology, Sestre milosrdnice Uni-
versity Hospital. All patients suﬀ ered from symptomatic 
tachycardia documented by 12-lead ECG and reported 
at least four episodes per year in the last three years. In 
AVRT group, 28 patients had overt preexcitation and 
ﬁ ve patients had concealed accessory pathway. Patients 
with bradycardia, AV block, sinus node dysfunction, 
hypotension, coronary artery disease, cerebrovascular 
disease, left ventricular hypertrophy (intraventricular 
septum IVS ≥14 mm), reduced left ventricular sys-
tolic function (ejection fraction <40%), renal or liver 
failure, and hypokalemia, as well as pregnant women 
were excluded from the study. Also, during the EPS 
electrophysiological study, patients with unsustained 
AVNRT or AVRT, as well as patients proven to have 
other arrhythmias were excluded from the study.
Study protocol and intervention
Each study patient was taken complete medical 
history and underwent physical examination, standard 
laboratory tests, chest x-ray, standard 12-lead ECG, and 
echocardiogram. At this time, all patients with struc-
tural heart disease were excluded from the study. All pa-
tients underwent (EPS) according to standard protocol, 
using four 6-French, quadripolar electrodes positioned 
under ﬂ uoroscopy in the right atrium, the right ventricular 
apex, the coronary sinus, and the bundle of His. Before 
EPS, a written informed consent was obtained from all 70 
patients. For EPS, conduction intervals and refractory pe-
riods were deﬁ ned in the conventional manner (AH, HV, 
PA and ERP)7,8. 
Tachycardia was induced by standard stimulation 
protocols using a Mingograph 62 Siemens stimulator; 
an incremental and programmed stimulation of the 
right or the left atrium, as well as an incremental and 
programmed stimulation of the right ventricular apex 
was done9,10. Following the induction of tachycardia 
and determination of its mechanism, propafenone was 
given intravenously (2 mg/kg over 10 minutes). Th e 
same electrophysiological protocol was repeated 30 
minutes after tachycardia termination to assess tachy-
cardia inducibility. During the EPS, vital parameters 
(blood pressure, ECG and oxygen saturation) were 
monitored.
AVNRT diagnostic criteria were as follows: 1) at 
tachycardia onset, signiﬁ cant prolongation of the AH-
interval (‘the jump’) recorded; 2) dual AV nodal an-
terograde conduction (i.e. the slow and the fast path-
way) veriﬁ ed; 3) during tachycardia, retrograde atrial 
activation occurred either before or simultaneously 
with the activation of ventricles; 4) during tachycar-
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dia, retrograde atrial activation occurred through the 
AV node; and 5) ventricular extra-stimulus, recorded 
while tachycardia was underway, did not interfere 
with the retrograde atrial activation. 
AVRT diagnostic criteria were as follows: 1) dur-
ing tachycardia, retrograde atrial activation occurred 
through the accessory pathway; 2) ventricular extra-
stimulus, recorded during tachycardia, pre-excited the 
atria during the bundle of His’ refractory period. 
Following the completion of the EP study, a stan-
dard ECG was recorded and compared to that ob-
tained prior to propafenone administration. 
Main outcome measure 
Th e main outcome measure was the successfulness 
of tachycardia termination and its re-induction rate 
subsequent to propafenone administration.
Statistical analysis 
Statistical analysis was carried out using the Sta-
tistica 6 software. Within this frame, Mann-Whitney 
U-test, χ2-test subject to Yates correction, T-test ap-
plicable to small independent samples, and Wilcoxon 
test were used. All results were considered statistically 
signiﬁ cant if yielding P<0.05. 
Results
Th e study included 70 patients, i.e. 37 with AVN-
RT (group 1) and 33 with AVRT (group 2), treated at 
Department of Cardiology, Sestre milosrdnice Univer-
sity Hospital. Demographic and clinical parameters 
of study patients are shown in Table 1. In all study 
patients, sustained tachycardia could be repeatedly in-
duced, most commonly by programmed atrial stimu-
lation, whereas fast atrial and ventricular stimulation 
was the most common way of terminating it. Electro-
physiological mechanisms underpinning tachycardia 
initiation are presented in Table 2. 
Following propafenone administration, tachycar-
dia was terminated in 28 of 37 (75.7%) AVNRT pa-
tients and 29 of 33 (87.9%) AVRT patients. Th e overall 
eﬃ  cacy of tachycardia termination was 81.42% (57 of 
Table 1. Demographic and clinical data on patients with atrioventricular nodal reentrant tachycardia (AVNRT, n=37) and 
atrioventricular reentrant tachycardia (AVRT, n=33) 





Age (yrs) median (min-max) 49 (21-70) 36 (18-70) 45 (18-70) P=0.002
Symptom duration (months) median (min-max) 120 (36-480) 96 (36-456) 109 (36-480)   P=0.133
Sex 
male, n (%) 17 (45.9) 19 (57.6) 36 (51.4) P=0.460
female, n (%) 20 (54.1) 14 (42.4) 34 (48.6) P=0.460
Symptoms
syncope 11(29.7) 13 (39.4) 24 (34.3) P=0.548
presyncope 6 (16.2) 8 (24.2) 14.(20) P=0.592
chest pain 3 (8.1) 1 (3.0) 4 (5.7) P=0.687
palpitations 28 (75.7) 23 (69.7) 51 (72.9) P=0.769
Treatment
propafenone 4 (10.8) 4 (12.1) 8 (11.4) P=0.837
atenolol 24 (64.9) 23 (69.7) 47 (67.1) P=0.864
verapamil 28 (75.7) 6 (18.2) 34 (48.6) P<0.001
sotalol 17 (45.9) 12 (36.4) 29 (41.4) P=0.574
amiodarone 14 (37.8) 14 (42.4) 28 (40.0) P=0.883
digoxin 3 (8.1) 1 (3.0) 4 (5.7) P=0.687
disopyramide 1 (2.7) 0 1 (1.4) P=0.953
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70 patients). In both patient groups, propafenone ad-
ministration was followed by a signiﬁ cant prolonga-
tion of PA, AH and HV intervals, atrial, ventricular 
and AV node eﬀ ective refractory periods (ERPs), right 
ventricular ERP in AVRT arm, thereby making an 
exception to the rule. Electrophysiological parameters 
obtained prior to and following propafenone adminis-
tration are shown in Table 3. Following propafenone 
administration and tachycardia termination, AVNRT 
managed to be re-induced in 12 (32.43%) and AVRT 
in 11 (33%) patients. Th e average re-induced tachy-
cardiac paces were signiﬁ cantly slower. In addition, 
in patients with re-induced AVNRT, a signiﬁ cant 
prolongation of AH and HV, but not VA interval 
was recorded while the arrhythmia was underway. 
Patients with re-induced AVRT showed prolonged 
HV and VA, but not AH interval. Electrophysiologi-
cal parameters pertinent to the induced tachycardia 
prior to and following propafenone administration are 
shown in Table 4. Complete VA-block was induced 
in eight (21.62%) AVNRT patients, whereas com-
plete VA block through the accessory pathway was 
induced in 12 (36.36%) AVRT patients. In AVRT 
arm, propafenone administration induced complete 
anterograde block through the accessory pathway in 
12 (42.85%) patients. In 20 patients with complete VA 
block, propafenone administration failed to re-induce 
tachycardia. Th e ECG obtained after the EP study 
revealed a signiﬁ cant PR and QRS prolongation, but 
no signiﬁ cant heart rate decrease (Table 5). 
During the course of the study, no propafenone-
related adverse eﬀ ects were recorded. 
Table 2. Mechanisms of tachycardia induction in patients with atrioventricular nodal reentrant tachycardia (AVNRT, n=37) 
and atrioventricular reentrant tachycardia (AVRT, n=33)
Tachycardia induction n (%)        AVNRT (n=37)
AVRT 
(n=33) Statistics
Programmed atrial stimulation 36 (97.3) 30 (90.1) P=0.449
Atrial stimulation with incremental frequency   8 (21.6)   6 (18.2) P=0.956
Programmed ventricular stimulation   4 (10.8) 12 (36.4) P=0.011
Ventricular stimulation with incremental frequency   4 (10.8)   5 (15.2) P=0.848
Table 3. Electrophysiological parameters recorded in patients with atrioventricular nodal reentrant tachycardia (AVNRT, 


















PA interval (ms) 25 (20-40) 30 (20-50) P<0.001 25 (10-30) 30 (10-45) P<0.001
AH interval (ms) 80 (60-115) 90 (70-130) P<0.001 80 (55-120) 90 (70-130) P<0.001
HV interval (ms) 50 (20-60) 50 (40-80) P<0.001 45 (10-60) 55 (10-70) P<0.001
AA interval (ms) 780 (500-1200) 800 (500-1100) P=0.062 800 (490-1200) 820 (550-940) P=0.060 
AV block cycle (ms) 320 (230-420) 380 (280-510) P<0.001 300 (220-460) 360 (280-420) P<0.001
ERP AV node (ms) 230 (160-300) 280 (200-420) P<0.001 220 (160-320) 245 (180-400) P<0.001
ERP - atrium (ms) 180 (140-240) 205 (160-260) P<0.001 180 (140-220) 200 (160-280) P<0.001
ERP - right 
ventricle (ms) 200 (160-240) 220 (200-240) P<0.001 200 (160-240) 200 (160-360) P=0.221 
Retrograde AV node 
ERP (ms) 220 (160-440) 350 (200-500) P<0.001 260 (180-300) 310 (280-460) P<0.001
VA block cycle 310 (220-460) 455 (320-750) P<0.001 240 (180-360) 280 (220-360) P=0.012
Book Acta 1-2010.indb   28 14.6.2010   9:22:54
Acta Clin Croat,  Vol. 49,  No. 1,  2010 29
H. Pintarić et al. Propafenone for atrioventricular tachycardia
Discussion
Study results indicated that 2 mg/kg intravenous 
propafenone successfully terminated AVRT and 
AVNRT. Th e overall eﬃ  cacy in tachycardia termi-
nation was 81.42%. In each study group, tachycardia 
failed to be re-induced in 67% of patients. Propafenone 
prolonged intracardiac intervals (AH, HV and PR) 
and signiﬁ cantly reduced the re-induced tachycardia 
rate. According to the joint ACC/AHA/ESC guide-
lines, the therapies of choice for an acute termination 
of supraventricular tachycardia are adenosine admin-
istration and vagal maneuvers5. 
Th ere are a number of studies that investigated the 
eﬃ  cacy of propafenone in supraventricular tachycar-
dia termination, however, generally including a small 
number of patients. Th e ACC/AHA/ESC guidelines 
lean on a study undertaken by Manolis et al., which in-
volved 11 AVRT patients. In this study, propafenone 
administration resulted in AP anterograde block re-
corded in four of nine, and retrograde block recorded 
in three of 11 patients. AVRT was no longer inducible 
in six of 11 patients11; the result is comparable to ours 
obtained in a larger study group. Th e limitation of our 
study was a relatively small number of patients, so the 
data obtained should be interpreted with caution. 
Adenosine and verapamil have both been studied 
and proved eﬃ  cient in supraventricular tachycardia 
termination. In 1991, Goy and Fromer studied the 
eﬃ  cacy of adenosine and verapamil in AVRT and 
AVNRT termination, and found both drugs to ter-
minate tachycardia in approximately 90% of cases12. 
In 2003, Cheng et al. compared the eﬃ  cacy of the two 
drugs in 122 patients with supraventricular tachycar-
dia. Adenosine terminated tachycardia in 86% and 
verapamil in 87.1% of cases13. In addition, a high in-
cidence of minor, but unpleasant side eﬀ ects in the 
adenosine arm, and an elevated risk of developing hy-
potension in the verapamil arm have been reported14. 
In our study, propafenone exhibited eﬃ  cacy in AVN-
RT and AVRT termination similar to that reported 
for adenosine and verapamil in the two studies men-
tioned above; therefore, propafenone could be consid-
ered as a drug of choice for termination of supraven-
tricular tachycardia in the emergency room setting, 
provided that patients under such treatment are free 
from any structural or ischemic heart disease whatso-
ever. Also, propafenone has a longer plasma half-life 
Table 4. Electrophysiological parameters pertinent to induced tachycardia in patients with atrioventricular nodal reentrant 


















Frequency (ms) 350 (260-500) 430 (340-600) P<0.001 340 (280-430) 430 (310-480) P<0.001
AH interval (ms) 380 (110-440) 340 (130-500) P<0.001 150 (90-280) 170 (100-240) P=0.132 
HV interval (ms) 47 (35-70) 55 (50-70) P<0.001 45 (30-60) 55 (50-70) P<0.001
VA interval (ms) 40 (5-180) 45 (15-160) P=0.113 130 (70-230) 150 (115-210) P<0.001
Table 5. ECG parameters in patients with atrioventricular nodal reentrant tachycardia (AVNRT, n=37) and atrioventricular 

















Frequency (o/min) 73 (53-100) 71 (50-97) 0.722 74 (55-98) 73 (51-98) 0.863
P-R interval (ms) 160 (120-200) 180 (120-240) P<0.001 140 (80-180) 180 (90-210) P<0.001
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than verapamil and adenosine, and therefore could be 
able to prevent early tachycardia recurrences15. Even 
in case of a tachycardia recurrence, propafenone is 
able to reduce tachycardiac pace, therefore probably 
reducing the symptoms as well9. During the course 
of our short-term follow up, no adverse reactions to 
propafenone were observed.
In conclusion, propafenone is a relatively safe and 
eﬀ ective antiarrhythmic drug, capable of AVNRT 
and AVRT termination. It could be considered as 
an alternative to adenosine and verapamil in patients 
with no structural or ischemic heart disease. 
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Sažetak
ELEKTROFIZIOLOŠKI UTJECAJ, UČINKOVITOST I SIGURNOST INTRAVENSKOG 
PROPAFENONA U OKONČANJU ATRIOVENTRIKULSKE NODALNE TAHIKARDIJE PONOVNOG 
ULAZA I ATRIOVENTRIKULSKE TAHIKARDIJE PONOVNOG ULAZA: PROSPEKTIVNA 
NERANDOMIZIRANA INTERVENCIJSKA STUDIJA
H. Pintarić, Š. Manola, J. Szavits Nossan, N. Pavlović, D. Delić-Brkljačić i V. Radeljić 
Cilj ove prospektivne nerandomizirane intervencijske studije bio je procijeniti elektroﬁ ziološki utjecaj, učinkovitost i 
sigurnost intravenskog propafenona u okončanju atrioventrikulske nodalne tahikardije ponovnog ulaza (AVNRT) i orto-
dromne atrioventrikulske tahikardije ponovnog ulaza (AVRT). Ispitivanje je provedeno u jednom centru, tj. u Kliničkoj 
bolnici “Sestre milosrdnice” u Zagrebu, od 1. siječnja 2005. do 31. prosinca 2006. godine. Uvjete za uključenje u studiju 
ispunjavalo je 70 bolesnika s AVNRT (n=37) i AVRT (n=33). Intervencija se sastojala od elektroﬁ ziološkog ispitivanja radi 
izazivanja tahikardije, nakon čega je slijedila intravenska primjena 2 mg/kg propafenona u objema skupinama. Glavne 
mjere ishoda bile su sigurnost i učinkovitost 2 mg/kg intravenskog propafenona u okončanju i ponovnom izazivanju tahi-
kardije. Od 37 bolesnika s AVNRT propafenon ju je uspješno okončao u 28 (75,7%) bolesnika, dok tahikardiju nije bilo 
moguće izazvati u 25 (67,56%) bolesnika. Od 33 bolesnika s AVRT propafenon ju je uspješno okončao u 29 (87,9%) bole-
snika, dok se se tahikardiju nije moglo izazvati u 22 (66,66%) bolesnika. Sveukupna učinkovitost propafenona u okončanju 
tahikardije bila je 81,42%. Za vrijeme studije nisu zabilježeni nikakvi štetni učinci povezani s propafenonom. Zaključuje 
se kako je propafenon siguran i učinkovit antiaritmik koji se može opravdano davati radi okončanja AVNRT i AVRT, te 
se može smatrati alternativom za adenozin i verapamil.
Ključne riječi: Antiaritmijski lijekovi – terapijska primjena; Propafenon – terapijska primjena; Tahikardija, supraventrukulska 
– terapija lijekovima; Elektroﬁ ziološke tehnike, srčane
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